EsoCap and Upadia sign exclusive licensing agreement combining EsoCap technology with Upadia antibodies for the treatment of Barrett’s esophagus
AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China
MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval